Company ProMIS Neurosciences, Inc. Toronto S.E.

Equities

PMN

CA74346M4065

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimerâs disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

Number of employees: 7

Managers	Title	Age	Since
Neil Warma CEO	Chief Executive Officer	61	13/21/13
Neil Cashman FOU	Founder	72	23/04/23
Eugene Williams CHM	Chairman	64	29/15/29
Daniel Geffken DFI	Director of Finance/CFO	67	22/17/22
Gavin Malenfant COO	Chief Operating Officer	61	22/21/22
Larry Altstiel CTO	Chief Tech/Sci/R&D Officer	74	19/22/19
Dennis Chen PRN	Corporate Officer/Principal	-	-
David Wishart PRN	Corporate Officer/Principal	-	27/21/27
Ernest D. Bush PRN	Corporate Officer/Principal	-	03/18/03
Johanne Kaplan PRN	Corporate Officer/Principal	64	21/16/21

Members of the board	Title	Age	Since
William Wyman BRD	Director/Board Member	86	08/14/08
Neil Cashman FOU	Founder	72	23/04/23
Neil Warma CEO	Chief Executive Officer	61	13/21/13
Eugene Williams CHM	Chairman	64	29/15/29
Patrick Kirwin BRD	Director/Board Member	67	29/15/29
Josh Mandel-Brehm BRD	Director/Board Member	41	01/21/01
Maggie Shafmaster BRD	Director/Board Member	65	22/21/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	18,961,116	14,347,158 ( 75.67 %)	0	75.67 %

Name	Equities	%	Valuation
Sphera Funds Management Ltd. 9.673 %	1,834,047	9.673 %	3 M $
Mike Gordon 6.112 %	1,158,846	6.112 %	2 M $
Ally Bridge Group HK Ltd 5.588 %	1,059,582	5.588 %	2 M $
Crocker Mountain LLC 5.304 %	1,005,726	5.304 %	2 M $
Jeremy Sclar 4.402 %	834,763	4.402 %	2 M $
Affinity Asset Advisors LLC 1.403 %	265,958	1.403 %	489 895 $
Eugene Williams 0.8435 %	159,930	0.8435 %	294 591 $
Neil Cashman 0.6061 %	114,921	0.6061 %	211 684 $
Northeast Financial Consultants, Inc. 0.5274 %	100,000	0.5274 %	184 200 $
Patrick Kirwin 0.4699 %	89,096	0.4699 %	164 115 $

Name	Equities	%	Valuation
Mike Gordon 42.86 %	30,000,000	42.86 %	55 M $

Name	Equities	%	Valuation
Mike Gordon 100.00 %	500,000	100.00 %	921 000 $
Jeremy Sclar 60.00 %	300,000	60.00 %	552 600 $

ProMIS Neurosciences, Inc.

1920 Yonge Street Suite 200

M4S 3E2, Toronto

+416 847 6898

http://www.promisneurosciences.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+15.19%	121B
REGENERON PHARMACEUTICALS, INC.	+19.91%	114B
BIONTECH SE	-19.80%	20.43B
GENMAB A/S	-16.06%	16.55B
BEIGENE, LTD.	-13.45%	16.45B
WUXI APPTEC CO., LTD.	-44.35%	15.59B
SAREPTA THERAPEUTICS, INC.	+66.67%	15.19B
NEUROCRINE BIOSCIENCES, INC.	+2.13%	13.54B
INSMED INCORPORATED	+119.39%	10.96B

Bio Therapeutic Drugs